Novel tetranuclear PdII and PtII anticancer complexes derived from pyrene thiosemicarbazones

Carolina G. Oliveira, Isolda Romero-Canelón, James P. C. Coverdale, Pedro Ivo S. Maia, Guy J. Clarkson, Victor M. Deflon, Peter J. Sadler

Research output: Contribution to journalArticlepeer-review


Cyclometallated palladium(II) and platinum(II) pyrenyl-derived thiosemicarbazone (H2PrR) complexes of the type [M4(μ-S-PrR-κ3-C,N,S)4] (M = PdII, PtII; R = ethyl, cyclohexyl) have been synthesised in good yields and fully characterised. X-ray crystallography showed that the tetranuclear complex [Pt4(μ-S-PrCh-κ3-C,N,S)4](CH3)2COCHCl3 contains an eight-membered ring of alternating M–S atoms. The ethyl derivatives [M4(μ-S-PrEt-κ3-C,N,S)4] exhibit potent antiproliferative activity towards A2780 human ovarian cancer cells, with IC50 values of 1.27 μM (for M = PdII) and 0.37 μM (for M = PtII), the latter being an order of magnitude more potent than the anticancer drug cisplatin (IC50 1.20 μM). These promising complexes had low toxicity towards non-cancerous human MRC5 cells, which points towards an early indication of differential toxicity between cancer and normal cells. Experiments that investigated the effects of these tetranuclear complexes on the cell cycle, integrity of the cell membrane, and induction of apoptosis, suggested that their mechanism of action of does not involve DNA targeting, unlike cisplatin, and therefore could be promising for combatting cisplatin resistance.
Original languageEnglish
Pages (from-to)9595-9604
JournalDalton Transactions
Issue number28
Publication statusPublished - 30 Jun 2020


Dive into the research topics of 'Novel tetranuclear PdII and PtII anticancer complexes derived from pyrene thiosemicarbazones'. Together they form a unique fingerprint.

Cite this